Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.
Pavlovic B, Bräutigam K, Dartiguenave F, Martel P, Rakauskas A, Cesson V, Veit M, Oechslin P, Gu A, Hermanns T, Saba K, Poyet C, Hötker AM, Rupp NJ, Valerio M, Derré L, Eberli D, Banzola I. Pavlovic B, et al. Among authors: dartiguenave f. Sci Rep. 2024 Aug 5;14(1):18148. doi: 10.1038/s41598-024-68026-1. Sci Rep. 2024. PMID: 39103428 Free PMC article.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: dartiguenave f. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R, Lozano LE, Anastasio A, Lofek S, Mastelic-Gavillet B, Navarro Rodrigo B, Nguyen S, Dartiguenave F, Rodrigues-Dias SC, Cesson V, Valério M, Roth B, Kandalaft LE, Redchenko I, Hill AVS, Harari A, Romero P, Derré L, Viganó S. Ahmed R, et al. Among authors: dartiguenave f. Cancers (Basel). 2023 Jun 8;15(12):3114. doi: 10.3390/cancers15123114. Cancers (Basel). 2023. PMID: 37370724 Free PMC article.
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I, Derré L, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias S, Dartiguenave F, Masnada A, Texeira-Pereira C, Benmerzoug S, Chevalier M, Domingos-Pereira S, Nguyen S, Polak L, Schneider A, Roth B, Jichlinski P, Nardelli-Haefliger D. Lucca I, et al. Among authors: dartiguenave f. Eur Urol Open Sci. 2022 Oct 3;45:55-58. doi: 10.1016/j.euros.2022.09.004. eCollection 2022 Nov. Eur Urol Open Sci. 2022. PMID: 36212980 Free PMC article.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Nguyen S, et al. Among authors: dartiguenave f. J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. J Immunother Cancer. 2022. PMID: 36002184 Free PMC article.
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: dartiguenave f. Eur Urol Open Sci. 2021 Nov 18;34:79-82. doi: 10.1016/j.euros.2021.10.001. eCollection 2021 Dec. Eur Urol Open Sci. 2021. PMID: 34825225 Free PMC article.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: dartiguenave f. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derrè L, Coukos G, Melero I, Harari A, Romero P, Viganó S, Kandalaft LE. Mastelic-Gavillet B, et al. Among authors: dartiguenave f. Eur J Cancer. 2020 Aug;135:173-182. doi: 10.1016/j.ejca.2020.04.036. Epub 2020 Jun 23. Eur J Cancer. 2020. PMID: 32590296 Free article.
Double Positive CD4+CD8+ T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
Bohner P, Chevalier MF, Cesson V, Rodrigues-Dias SC, Dartiguenave F, Burruni R, Tawadros T, Valerio M, Lucca I, Nardelli-Haefliger D, Jichlinski P, Derré L. Bohner P, et al. Among authors: dartiguenave f. Front Immunol. 2019 Mar 29;10:622. doi: 10.3389/fimmu.2019.00622. eCollection 2019. Front Immunol. 2019. PMID: 30984190 Free PMC article. Clinical Trial.
15 results